BioCentury
ARTICLE | Clinical News

Human anti-rabies IgG therapy regulatory update

November 9, 2016 10:01 PM UTC

FDA accepted for review a BLA from Kamada for its human anti-rabies IgG therapy as post-exposure treatment of rabies infection. The PDUFA date is Aug. 29, 2017. Kedrion Group S.p.A. (Barga, Italy) has...

BCIQ Company Profiles

Kamada Ltd.

Kedrion S.p.A.